

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/529,221
				Filing Date	June 30, 2006
				First Named Inventor	ROBERT, Bruno
				Art Unit	1644
				Examiner Name	DIBRINO, Marianne N.
				Attorney Docket Number	1843.0200001/EJH/M-N
Sheet	1	of	1		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/M.D./	NPL97	Hermans, I.F., "Dendritic Cell Function Can Be Modulated through Cooperative Action of TLR Ligands and Invariant NKT Cells," <i>J. Immunol.</i> 178:2721-2729, The American Association of Immunologists, Inc. (March 2007)	
	NPL98	Nagarajan, N.A., and Kronenberg, M., "Invariant NKT Cells Amplify the Innate Immune Response to Lipopolysaccharide," <i>J. Immunol.</i> 178:2706-2713, The American Association of Immunologists, Inc. (March 2007)	
	NPL99	Parekh, V.V., <i>et al.</i> , "The <i>In Vivo</i> Response of Invariant Natural Killer T Cells to Glycolipid Antigens," <i>Int. Rev. Immunol.</i> 26:31-48, Taylor & Francis (January-April 2007)	
	NPL100	Silk, J.D., <i>et al.</i> , "Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy," <i>J. Clin. Invest.</i> 114:1800-1811, American Society for Clinical Investigation (December 2004)	
	NPL101	Stirmemann, K., <i>et al.</i> , "Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice," <i>J. Clin. Invest.</i> 118:994-1005, American Society for Clinical Investigation (March 2008)	
	NPL102	Stronge, V.S., <i>et al.</i> , "A closer look at CD1d molecules: new horizons in studying NKT cells," <i>Trends Immunol.</i> 28:455-462, Elsevier Science Ltd. (October 2007)	
↓	NPL103	Van Kaer L., "NKT cells: T lymphocytes with innate effector functions," <i>Curr. Opin. Immunol.</i> 19:354-364, Elsevier Ltd. (June 2007)	
/M.D./	NPL104	Co-pending U.S. Application No. 12/034,737, inventors Zauderer, M., <i>et al.</i> , filed February 21, 2008 (NOT PUBLISHED)	

792976v1

Examiner Signature	/Marianne DiBrino/	Date Considered	08/17/2009
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.